Cite

    Johnson, D. et al. (n.d.). 320 Study design and interim recruitment into the post-authorization safety study to monitor pregnancy and infant outcomes following administration of dupilumab during planned or unexpected pregnancy in North America. British journal of dermatology. p. . [Online].